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Overexpression of HER2 is associated with an adverse prognosis in breast cancer. Despite this, the mechanism of its transcriptional
regulation remains poorly understood. PEA3, a MAP kinase (MAPK)-activated member of the Ets transcription factor family has been
implicated in the transcriptional regulation of HER2. The direction of its modulation remains controversial. We assessed relative levels
of PEA3 expression and DNA binding in primary breast cultures derived from patient tumours (n¼18) in the presence of an
activated MAPK pathway using Western blotting and shift analysis. Expression of PEA3 in breast tumours from patients of known
HER2 status (n¼107) was examined by immunohistochemistry. In primary breast cancer cell cultures, growth factors induced
interaction between PEA3 and its DNA response element. Upregulation of PEA3 expression in the presence of growth factors
associated with HER2 positivity and axillary lymph node metastasis (P¼0.034 and 0.049, respectively). PEA3 expression in breast
cancer tissue associated with reduced disease-free survival (Po0.001), Grade III tumours (Po0.0001) and axillary lymph node
metastasis (P¼0.026). Co-expression of PEA3 and HER2 significantly associated with rate of recurrence compared to patients who
expressed HER2 alone (P¼0.0039). These data support a positive role for PEA3 in HER2-mediated oncogenesis in breast cancer.
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HER2 encodes for a 185kDa transmembrane glycoprotein receptor
which is structurally related to the epidermal growth factor receptor
family. Overexpression of HER2 occurs in 20–30% of breast cancer,
and is associated with poorly differentiated and highly proliferative
tumours (Sorlie et al, 2001). These tumours tend to be resistant to
endocrine therapies and are associated with a decrease in overall
survival (Berns et al, 1995; Carlomagno et al,1 9 9 6 ) .T h em o n o c l o n a l
antibody, trastuzumab (herceptin), targets the HER2 receptor and is
an effective therapy in recurrent breast cancers that overexpress
HER2 (Vogel et al, 2002). Despite the prognostic significance of
HER2 and the existence of a therapeutic agent, many questions
about HER2’s role and that of trastuzumab remain. Unfortunately,
just as oestrogen receptor (ER) status imperfectly predicts response
to endocrine therapy, HER2 expression imperfectly predicts
response to trastuzumab (Menard et al, 2003). In addition, despite
the increased aggressiveness associated with HER2 overexpression,
the precise mechanism of HER2 regulation is incompletely under-
stood. Previous studies have implicated growth factor-related
transcription factors in HER2 overexpressing breast cancers (Goel
and Janknecht, 2003). Ets proteins are a family of mitogen-activated
protein kinase (MAPK)-dependant transcription factors. They have
been shown to be present in primary human breast cancers and
their expression has been associated with disease progression and
metastasis (Shepherd et al, 2001; Span et al, 2002). Ets transcription
factors regulate target gene expression by binding to Ets response
elements in the promoter region of the relevant target gene. The
HER2 upstream regulatory region contains a conserved Ets-binding
site and mutation of this sequence reduces transcription of linked
reporter genes in several different mammalian cell lines, including
breast tumour cell lines (Scott et al, 1994). These findings are
consistent with the hypothesis that one of the Ets proteins may
regulate transcription of the HER2 gene and may account for its
increased expression in breast tumour cells. PEA3 (E1AF) is an Ets
family member, and previous molecular studies have implicated
PEA3 in the regulation of HER2 transcription. Shepherd et al (2001)
has suggested that PEA3 has the potential to positively regulate
HER2 transcription. Conversely, another study suggests that PEA3
represses HER2 promoter-reporter expression in a human ovarian
and a human breast carcinoma cell line (Xing et al, 2000), and Xia
et al (2006) have suggested that PEA3 expression does not correlate
with HER2 expression in human breast cancer. These conflicting
studies prompted us to undertake ex vivo studies in human breast
tissue and in primary cell cultures derived from patient tumours.
We hypothesise that PEA3 expression may be associated either
directly or indirectly with HER2 status and that it may be influenced
by an activated MAPK pathway. We propose that the direction of
these relationships would support either a positive or a negative role
for PEA3 in HER2-mediated breast tumorigenesis.
MATERIALS AND METHODS
Patient selection
Following ethical approval, 107 breast tumour specimens and six
reduction mammoplasties were included in this study. All patients
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swere free of distant metastasis at presentation and were assessed
by abdominal ultrasound, chest X-ray and bone scintigraphy
before surgery. All patients received chemotherapy and tamoxifen
(20mgday
 1) for a maximum of 5 years. In those patients who
were ER-negative, tamoxifen was prescribed on the basis of the fact
that the patients were PR-positive.
Cell culture stimulations
Following ethical approval, breast tumour specimens were
obtained from 18 patients undergoing surgery for removal of a
histologically confirmed breast tumour. Breast tumour cell
cultures were established and validated as described previously
(Myers et al, 2004, 2005). In brief, primary tumour epithelial cells
were extracted in HBSS without calcium or magnesium (Gibco,
Paisley, Scotland) supplemented with 1mM EDTA and 1mM DTT for
40min. Cells were cultured in RPMI containing 5mgml
 1 insulin,
10mgml
 1 transferrin, 30nM sodium selinate, 10nM hydrocorti-
sone, 10nM b-estradiol, 10mM HEPES, 2mM glutamine, 10% foetal
calf serum (wv
 1) and 5% ultroser G on a growth factor-reduced
matirgel matrix (BD Biosciences, San Jose, CA, USA) (60ngcm
 2).
Examination of primary breast cultures by staining with ethidium
bromide and flow cytometric analysis using the phycoerythrin
(PE)-labelled pan-leukocyte marker (CD45 RA and RO), confirmed
cell viability and epithelial origin of tumour cells (Myers et al,
2004). Phenotypically distinct progenitor epithelial cell popula-
tions within the mammary epithelium were characterised by flow
cytometry using a PE-conjugated mouse anti-human EpCAM
(epithelial-specific antigen) antibody and FITC-conjugated mouse
anti-human CD227 (MUC1) monoclonal mouse antibody (BD
Biosciences). Bipotent progenitors (EpCAM
þMUC1
 ) which can
generate both luminal and myoepithelial cells were found to
represent 51.9% of the epithelial cell population, whereas the
luminal-restricted progenitor (EpCAM
þ MUC
þ) were found to
represent 48.1%. Cells were incubated in a humidified atmosphere
of 5% CO2 at 371C. Experiments were carried out when cells
reached 90% confluence. Cells were serum and steroid depleted for
24h before treatment and then incubated in the presence and
absence of bFGF or EGF for 24h and harvested. Total protein was
extracted using lysis buffer (1% Ipegal, 0.5% deoxycholic acid,
0.1% SDS and 1 PBS) with pefabloc (5mgml
 1). Cell lysates were
subsequently normalised for protein content.
Western blotting
Proteins (100mg) were resolved on a 12% polyacrylamide gel at
110V for 120min and were transferred to a nitrocellulose
membrane (250mA for 60min). Membranes were incubated for
60min in blocking buffer (5% non-fat dry milk, 0.1% Tween in
PBS) at room temperature and subsequently with primary
antibody, mouse anti-human PEA3 (10mgml
 1) (Santa Cruz
Biotechnology Inc., Sc-113) in blocking buffer overnight at 41C.
The membranes were washed before incubation with the
corresponding horseradish peroxidase secondary antibody (Santa
Cruz Biotechnology Inc.) (one in 2000) in blocking buffer for
60min at room temperature. The membranes were washed and
developed with intensified luminescence (Pierce, IL, USA). K-562
cells (Santa Cruz Biotechnology Inc.) were used as a positive
control for PEA3.
Electrophoretic mobility shift assays
Nuclear protein was extracted using a Ner/Per kit according to the
manufacturer’s instructions (Pierce). For electrophoretic mobility
shift assay, 1mg of nuclear extract was incubated for 30min in the
presence of 20mM HEPES (pH 7.9), 5mM MgCl2, 20% glycerol,
100mM KCl, 0.2mM EDTA, 8% Ficoll, 600mM KCl, 500ngml
 1 poly
dI dC (deoxyinosinic-dexycytidylic) acid, 50mM DTT and a
32P-
dCTP-labelled double-stranded oligonucleotide for Ets, response
element. Oligonucleotides were designed to incorporate the native
human HER2/ERBB2 (NM_001005852) promoter ( 287 to  270)
50-CATGGCCTAGGGAATTTATCC-30, with the consensus se-
quence of Ets-binding elements underlined. For supershift
experiments, antibodies against PEA3 were added following the
initial incubation, and samples were then incubated for a further
20min. The samples were electrophoresed through a 5.5%
nondenaturing polyacrylamide gel in 0.5  Tris-borate-EDTA
buffer. For competition studies, the reaction was performed as
described with 50  molar excess of unlabelled probe. Supershift
negative controls were performed using matched IgG control.
Immunohistochemistry and immunofluorescence
Five micron thick tissue sections were cut from paraffin-embedded
breast tumour tissue blocks and mounted on Superfrost Plus slides
(BDH, Poole, UK). Sections were dewaxed, rehydrated and washed
in PBS. PEA3 was detected as described previously (Fleming et al,
2004). Briefly, sections were blocked in serum for 90min. Sections
were incubated with the primary antibody, mouse anti-human
PEA3 (10mgml
 1) and rabbit anti-human Phospho-raf (1:50)
(Cell signalling, Beverly, MA, USA) for 60min at room tempera-
ture. Subsequently, sections were incubated in the corresponding
biotin-labelled secondary antibody (one in 2000) for 30min,
followed by peroxidase-labelled avidin–biotin complex. Sections
were developed in 3, 3-diaminobenzidine (DAB) tetrahydrochlo-
ride and counterstained with haematoxylin. Negative controls
were performed using matched IgG controls (DAKO, Glostrup,
Denmark). Immunostained slides were scored for PEA3 and
Phospho-raf using the Allred scoring system (Harvey et al, 1999).
HER2 status was evaluated using the DAKO (Glostrup, Denmark)
HercepTest immunocytochemical assay. Scoring was assessed
according to the manufacturer’s instructions. A score was assigned
according to the intensity and pattern of cell membrane staining: 0
to þ1¼no staining, or staining in o10% of cells; þ2¼weak to
moderate staining in 410% of cells; þ3¼strong staining in
410% of cells. Sections were examined under a light microscope.
Independent observers, without knowledge of prognostic factors,
scored slides. Immunofluorescence detection of PEA3 was
performed on primary breast cancer tissue. Cells and tissues were
prepared as described above. Breast cancer cells and sections were
blocked in 1.5% normal serum and then incubated with 20mgml
 1
mouse anti-human PEA3 in 10% human serum for 90min. Cells
and sections were subsequently incubated with Alexa Fluor 546-
conjugated secondary antibody (Molecular Probes, Invitrogen,
Paisley, UK) for 60min and were counterstained with DAPI
(Sigma-Aldrich, Dorset, UK). Confocal microscopy was performed
using a confocal microscope (Zeiss LSM 510 UV META system,
Standart Gottingen, Germany) and images were captured using
Laser Capture software, Zeiss, Standart Gottingen, Germany.
Clinicopathological parameters
Variables analysed included tumour grade, axillary nodal status
and ER status. A recurrence was defined as any local (chest wall) or
systemic recurrence during the follow-up period.
Statistical analysis
Statistical analysis was carried out using the Fisher’s exact test for
categorical variables to compare two proportions. Kaplan–Meier
estimates of survival functions were computed and the Wilcoxon
test was used to compare survival curves. In addition, the
Wilcoxon rank sum test was used to compare two medians.
Two-sided P-values of o0.05 were considered to be statistically
significant.
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Growth factor induction of PEA3 and recruitment to the
HER2 promoter in breast cancer cells
The ability of growth factors bFGF and EGF to induce PEA3
expression in primary breast cancer cells derived from patient
tumours was investigated by Western blotting. The transcription
factor was expressed in a proportion of tumours (14 out of 18
tumours). Of tumours found positive for PEA3, increased
expression was found in a subset of tumours in response to
growth factor treatment (Figure 1A).
To determine the ability of PEA3 to bind to the Ets response
element in the presence of growth factors, bFGF and EGF, gel shift
assays were performed. Using oligonucleotide sequences, which
are specific for the HER2 promoter, the ability of nuclear extracts
from non-treated, primary breast cancer cell cultures to bind to the
DNA response element was compared to cells treated with bFGF
and EGF (Figure 1B). PEA3 response element binding was induced
in the presence of both bFGF and in particular EGF in comparison
to control. An immuno-depletion induced by pre-incubation of the
nuclear extracts with anti- PEA3 established that PEA3 was present
at the protein–DNA complex.
Localisation of PEA3 and Phospho-raf in human breast
cancer
The transcription factor PEA3 was localised within paraffin-
embedded human breast tissue using immunohistochemistry.
PEA3 was detected predominantly within the nuclei of invasive
tumour epithelial cells, and to a lesser extent within the cytosol
(Figure 2A). PEA3 protein was not detected in the normal
surrounding breast tissue nor in the reduction mammoplasties,
which were used as controls. This predominant nuclear localisa-
tion was confirmed by immunofluorescence (Figure 2C). PEA3 was
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Figure 1 (A) Western blot analysis of PEA3 protein levels in primary breast cultures. Illustrative blots of primary tumour response to stimulation with
either bFGF (5ngml
 1) or EGF (10ngml
 1). Positive controls, K-562 (þ). Relative optical density of PEA3 immunoblots were obtained (Eagle Eye,
Stratagene, CA, USA), optical density readings of control values were normalised to 1 and treated groups were expressed as a ratio. Results are expressed as
mean7s.e.m. (n¼18). (B) Electrophoretic mobility shift analysis of nuclear extracts primary breast cancer cultures. Nuclear protein extracts from primary
breast cancer cells in the presence and absence of bFGF and EGF were compared for increased binding to an a
32P-dCTP labelled Ets response element.
DNA protein interactions were assayed in the presence of 50  molar excess of homologous oligonucleotide. Nuclear protein extracts were pre-incubated
in the presence of anti-PEA3. Negative controls were performed using matched IgG. Relative optical densities of PEA3 immunoblots were performed.
Optical density readings of control values were normalised to 1 and treated groups were expressed as a ratio. Results are expressed as mean7s.e.m.
(n¼3).
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sfound to be expressed in 47% of breast tumour patients. As
reported previously, expression of Phospho-raf was found within
the nuclei of tumour epithelial cells with scant cytoplasmic
staining (Myers et al, 2005) (Figure 2B).
Associations between the expression of PEA3 and clinical
variables/growth factor markers
Associations between the qualitative expression of PEA3 and
clinicopathological parameters were examined. Expression of the
transcription factor, PEA3, was found to associate with both
tumour grade and axillary lymph node positivity (Po0.0001 and
0.026, respectively). A significant association was found between
disease recurrence and expression of PEA3 (Po0.0001). No
relationship was detected between the transcription factor and
ER status (Table 1). From Kaplan–Meier estimates of survival,
PEA3 protein was found to significantly associate with time to
disease recurrence (Po0.001, n¼107) (Figure 3A).
In line with previous observations (Fleming et al, 2004), a
significant association was detected between PEA3 expression and
that of HER2 (P¼0.0369) (Table 1). The ability of breast cancer
cells derived from patient tumours to regulate PEA3 protein
expression in the presence of growth factors was related to
clinicopathological parameters. Upregulation of PEA3 was de-
tected in 66% (12 out of 18 tumours) of tumours. Relative
increases in PEA3 protein expression are given in Table 2. Growth
factor induction of PEA3 expression was found to significantly
associate with axillary lymph node positivity and expression of
HER2 (P¼0.049 and P¼0.034, respectively). Co-expression
of HER2 and PEA3 significantly associated with increased rate of
recurrence, compared to patients who expressed HER2, but not
PEA3 (P¼0.0039, n¼32) (Figure 3B). In order to determine the
association between PEA3 status and an activated MAPK pathway,
expression of the MAPK protein Phospho-raf was examined.
Phospho-raf expression significantly associated with PEA3 expres-
sion (Po0.0001) (Table 1).
DISCUSSION
The HER2 (erbB2) gene encodes a 185-kDa transmembrane
receptor with tyrosine kinase activity and acts through intracellular
IgG Control PEA3 IgG Control Normal
C Raf IgG Control Normal Control
DAPI Anti-PBA3+DAPI Anti-PBA3
A
B
C
Figure 2 (A) Immunohistochemical localisation of PEA3 ( 200) counterstained with haematoxylin and matched IgG-negative controls in human breast
cancer tissue. (B) Immunohistochemical localisation of Phospho-raf ( 200) counterstained with haematoxylin and matched IgG-negative controls in human
breast cancer tissue. (C) Immunofluoresence localisation of PEA3 (green) in human breast cancer tissue ( 630) counterstained with DAPI (blue).
Table 1 Comparison of PEA3 expression with clinicopathological
parameters and growth factor markers
Total
PEA3-positive
(%)
PEA3-negative
(%) P-value
No. of patients 107 50 (47%) 57 (53%) —
Mean age 47.94 51.90 0.0776
Tumour size (mm) 3.17 2.72 0.0198
Grade
Grade 3 55 37 (67%) 18 (33%)
Non-grade 3 52 13 (25%) 39 (75%) o0.0001
Axillary lymph node status
Node-positive 69 38 (55%) 31 (45%)
Node-negative 38 12 (32%) 26 (68%) 0.0260
ER status
Positive 84 40 (48%) 44 (52%)
Negative 23 10 (43%) 13 (57% 0.8154
HER2 status
Positive 32 20 (63%) 12 (37%)
Negative 75 30 (40%) 45 (60%) 0.0369
Recurrence
Positive 23 20 (87%) 3 (13%)
Negative 84 30 (36%) 54 (64%) o0.0001
Phospho-raf
Positive 37 31 (84%) 6 (16%) o0.0001
Negative 70 19 (27%) 51 (73%)
ER¼oestrogen receptor. Continuous variables were analysed using the two-sample
t-test. Nominal variables were analysed using Fisher’s exact test.
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ssignal transduction pathways to alter gene expression. HER2
overexpression is associated with aggressive breast cancers and an
adverse prognosis. Trastuzumab (herceptin) is a monoclonal
antibody which targets HER2 and combination chemotherapy with
trastuzumab is now a standard first-line treatment for women with
advanced HER2 overexpressing breast cancer (Vogel et al, 2002).
Recent data support trastuzumab’s role in earlier stages of disease
(Romond et al, 2005). Despite these advances, a number of
questions remain regarding the exact role of HER2 in breast
tumour progression including the exact mechanism of HER2
transcriptional regulation. The Ets family of transcription factors
play a well-documented role in breast tumour progression and have
been shown to contribute to the transcriptional regulation of HER2
(Shepherd et al, 2001; Span et al, 2002). We have previously
demonstrated that the growth factor EGF induces HER2 protein
expression in primary breast cultures derived from patient
tumours, thus implicating an activated MAPK pathway in HER2
transcriptional regulation (Myers et al, 2005). To date, assessing
endogenous PEA3 protein expression in human breast cancer cell
lines has proved difficult. Here, we demonstrate an upregulation in
PEA3 protein expression and DNA binding within the HER2
promoter in the presence of an activated MAPK pathway and
describe a relationship between regulation of PEA3 expression in
response to growth factor stimulation and HER2 positivity in
primary breast tumour cultures. In this study, we describe
associations between co-expression of PEA3 and HER2 and time
to disease recurrence.
Ets family members can be divided into 13 subgroups based on
the sequence similarity of their Ets domains. PEA3 is a founding
member of a subfamily of class I Ets transcription factors that also
includes ER81 and ERM (Xin et al, 1992). The Ets family of
transcription factors contribute to the transcriptional regulation of
HER2 (Shepherd et al, 2001). The exact role of PEA3 in HER2
transcriptional regulation remains controversial with conflicting
reports as to the direction of its modulation (Xing et al, 2000;
Shepherd et al, 2001). Ets transcription factors are known effectors
of the MAPK pathway, (O’Hagan et al, 1996), and class I family
members, in particular, are targets for phosphorylation in
response to stimulation. Phosphorylation of Ets sub-family
members, Ets-1 and Ets-2, by MAPK-dependent pathways leads
to persistent expression of tumour-related target genes including
proteases such as uPA and MMPs (Yang et al, 1996; Sharrocks
et al, 1997). In vitro studies provide evidence that PEA3 can be
activated through phosphorylation by MAPK pathway, both
through the extracellular signal-related kinase and the c-Jun N-
terminal kinase stress-activated protein kinase (Wasylyk et al,
1997). Phosphorylation via an activated MAPK pathway also
represents a potential mechanism of activation of PEA3-DNA-
binding (O’Hagan et al, 1996). We found that both the growth
factors, bFGF and EGF, induced interaction between PEA3 and its
response element, within the promoter region of HER2. In this
study, growth factors, bFGF and EGF upregulated the protein
expression of PEA3 in human primary tumour cell cultures.
Furthermore, response to growth factor stimulation in primary
breast tumour cultures associated with axillary lymph node
positivity and HER2 overexpression supporting a positive role
for PEA3 in breast cancer progression.
A previous study by Kinoshita et al (2002) observed PEA3
protein to be expressed exclusively in tumour tissue. We have
previously correlated PEA3 protein expression with that of HER2
in a limited cohort of breast cancer patients (Fleming et al, 2004).
In this study, we have examined the expression of PEA3 in relation
to established clinical parameters of breast cancer. We found a
positive association between PEA3 protein expression and tumour
grade and axillary lymph node positivity, known poor prognostic
indicators in breast cancer. In addition, PEA3 expression
correlated with time to disease recurrence. Co-expression of
PEA3 and HER2 significantly increased the rate of disease
recurrence supporting a positive role for PEA3 in HER2-mediated
oncogenesis.
Associations between co-expression of PEA3 and HER2 and
reduced disease-free survival and between upregulation of PEA3
protein expression, in primary cultures, and both axillary lymph
node positivity and HER2 overexpression are suggestive of a positive
role for PEA3 in HER2-mediated breast tumour progression.
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Figure 3 (A) Kaplan–Meier estimates of disease-free survival (DFS)
(n¼107) according to PEA3 expression. (B) DFS according to PEA3
expression in HER2-positive breast tumour patients (n¼32).
Table 2 Relative levels of protein expression of PEA3 in primary breast
tumour cell cultures in the presence of growth factors, n¼18
PEA3stimulated – PEA3control P-value
No. of positive patients 14/18
HER2 status (median and range)
Positive 534 (200–860) 0.034
Negative 124 (0–340)
Axillary status (median and range)
Positive 338 (160–660) 0.049
Negative 80 (0–210)
Relative optical density of PEA3 immunoblots both under control conditions and
following stimulation with growth factors were obtained. Optical density readings
were normalised to 1 and treated groups were expressed as a ratio. Data expressed
as median and range, comparisons analysed using Wilcoxon rank sum test. These
data are also represented graphically in the form of a histogram.
PEA3 and HER2 in breast cancer
E Myers et al
1408
British Journal of Cancer (2006) 95(10), 1404–1409 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sREFERENCES
Berns EM, Foekens JA, Van Staveren IL, Van Putten WL, de Koning HY,
Portengen H, Klijn JG (1995) Oncogene amplification and prognosis in
breast cancer: relationship with systemic treatment. Gene 159: 11–18
Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A,
Pettinato G, Panico L, D’Antonio A, Bianco AR, De Placido S (1996) C-
erb B2 overexpression decreases the benefit of adjuvant tamoxifen in
early-stage breast cancer without axillary lymph node metastasis. J Clin
Oncol 14: 2702–2708
Fleming FJ, Myers E, Kelly G, Crotty TB, McDermott EW, O’Higgins NJ, Hill
AD, Young LS (2004) Expression of SRC-1, AIB1 and PEA3 in HER2
mediated endocrine resistant breast cancer; a predictive role for SRC-1.
J Clin Pathol 57: 1069–1074
Goel A, Janknecht R (2003) Acetylation-mediated transcriptional activation
of the Ets protein ER81 by p300. P/CAF and HER2/Neu. Mol Cell Biol 23:
6243–6254
Harvey JM, Clark GM, Osbourne CK, Allred DC (1999) Estrogen receptor
status by immunohistochemistry is superior to ligand binding assay for
predicting response to adjuvant endocrine therapy in breast cancer.
J Clin Oncol 17: 1474–1481
Kinoshita J, Kitamura K, Tanaka S, Sugimachi K, Ishida M, Saeki H (2002)
Clinical significance of PEA3 in human breast cancer. Surgery 131(Suppl
1): S222–S225
Menard S, Pupa SM, Campiglio M, Tagiabue E (2003) Biologic and
therapeutic role of HER2 in cancer. Oncogene 22: 6570–6578
Myers E, Fleming FJ, Crotty TB, Kelly G, McDermott EW, O’Higgins NJ, Hill
AD, Young LS (2004) Inverse relationship between ER b and SRC-1
predicts outcome in endocrine resistant breast cancer. Br J Cancer 91:
1687–1693
Myers E, Hill AD, Kelly G, McDermott EW, O’Higgins NJ, Buggy Y, Young
LS (2005) Associations and interactions between Ets-1 and Ets-2 and
co-regulatory proteins SRC-1, AIB1 and NCoR in breast cancer.
Clin Cancer Res 11: 2111–2122
O’Hagan RC, Tozer RC, Symons M, McCormick F, Hassell JA (1996) The
activity of the Ets transcription factor PEA3 is regulated by two distinct
MAPK cascades. Oncogene 13: 1323–1333
Romond EH, Prez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE,
Tan Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisonsky TM,
Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G,
Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM,
Ingle JN, Walmark N (2005) Trastuzumab plus adjuvant chemotherapy
for operable Her2 positive breast cancer. N Engl J Med 53: 1673–1684
Scott GK, Daniel JC, Xiong X, Maki RA, Kabat D, Benz CC (1994) Binding of
an ETS-related protein within the DNase I hypersensitive site of the
HER2/neu promoter in human breast cancer cells. J Biol Chem 269:
19848–19858
Sharrocks AD, Brown AL, Ling Y, Yates PA (1997) The ETS-domain
transcription factor family. Int J Biochem Cell Biol 29: 1371–1387
Shepherd TG, Kockeritz L, Szrajbe MR, Muller WJ, Hassell JA (2001) The
pea3 subfamily ets genes are required for HER2/Neu-mediated mammary
oncogenesis. Curr Biol 11: 1739–1748
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T,
Eisen MB, Van de Rijn M, Jeffrey SS, Thornsen T, Quist H, Matese JC,
Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001)
Gene expression patterns of breast carcinomas distinguish tumour
subclasses with clinical implications. Proc Natl Acad Sci USA 98:
10869–10874
Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, Sweep CG
(2002) Expression of the transcription factor Ets-1 is an independent
prognostic marker for relapse-free survival in breast cancer. Oncogene
21: 8506–8509
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L,
Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ,
Press M (2002) Efficacy and safety of trastuzumab as a single agent in
first line treatment of HER2 overexpressing metastatic breast cancer.
J Clin Oncol 20: 719–726
Wasylyk C, Bradford AP, Gutierrez-Hartman A, Wasylyk B (1997)
Conserved mechanisms of Ras regulation of evolutionary related
transcription factors Ets-1 and Pointed P2. Oncogene 14: 899–913
Xia WY, Lien HC, Wang X, Pan Y, Sohin A, Kuo YH, Chang KJ, Zhou X,
Wang H, Yu Z, Hotobagyi G, Shi DR, Hung MC (2006) Expression of
PEA3 and lack of correlation between PEA3 and HER-2/neu expression
in breast cancer. Breast Cancer Res Treat 98: 295–301
Xin JH, Cowie A, Lachance P, Hassell JA (1992) Molecular cloning and
characterization of PEA3, a new member of the Ets oncogene family
that is differentially expressed in mouse embryonic cells. Genes Dev 6:
481–496
Xing X, Wang SC, Xia W (2000) The ets protein PEA3 suppresses
HER-2/neu over expression and inhibits tumorigenesis. Nat Med 6:
189–195
Yang BS, Hauser CA, Henkel G (1996) Ras mediated phosphorylation of a
conserved threonine residue enhances the transactivation activities of c-
Ets-1 and c-Ets-2. Mol Cell Biol 16: 538–547
PEA3 and HER2 in breast cancer
E Myers et al
1409
British Journal of Cancer (2006) 95(10), 1404–1409 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s